Merck, Teva End Cancidas Patent Fight

Law360, New York (March 2, 2011, 1:15 PM EST) -- Merck & Co. Inc. on Wednesday resolved a suit in New Jersey seeking to prevent Teva Pharmaceuticals USA Inc. from marketing a generic version of anti-fungal drug Cancidas.

Judge Stanley Chesler of the U.S. District Court for the District of New Jersey dismissed Merck’s infringement action in light of the litigants' decision to settle their differences rather than proceed toward a trial this fall.

Details of the settlement remain confidential, save that each side is covering its own costs and fees racked up over roughly 15...
To view the full article, register now.